Bladder Cancer Clinical Trials in San Francisco, California

10 studies are recruiting for bladder cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

   The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical center Parnassus, San Francisco, California

   Locations

   16 in total

   Run by

   EvolveImmune United, Inc

   See if you can join NCT07217171 on ClinicalTrials.gov

2. KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

   Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center at Mission Bay ( Site 5044), San Francisco, California

   Locations

   16 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07232602 on ClinicalTrials.gov

3. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

   This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Research Site, San Francisco, California

   Locations

   100 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07129993 on ClinicalTrials.gov

4. Predicting BCG Response

   To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possess…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   UCSF, San Francisco, California

   Locations

   6 in total

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT04564781 on ClinicalTrials.gov

5. Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

   This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer. Standard of care treatment for muscle invasive bladder cancer is chemotherapy, …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT06470282 on ClinicalTrials.gov

6. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

7. A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

   Voided urinary cytology (VUC) is the most widely used urine-based assay for detecting bladder cancer (BCa); however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most curable. Furthermore, the detection rate of VUC for recurrent BCa is not much better. Because of …

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   4 in total

   Run by

   Cedars-Sinai Medical Center

   See if you can join NCT03193515 on ClinicalTrials.gov

8. Blue Light Cystoscopy With Cysview® Registry

   Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   23 in total

   Run by

   Photocure

   See if you can join NCT02660645 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, San Francisco, California

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

10. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov